New combo therapy aims to fix dangerous low platelet counts in cancer patients
NCT ID NCT07334093
First seen Jan 12, 2026 · Last updated May 01, 2026 · Updated 18 times
Summary
This study tests whether combining two drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients whose platelet levels drop dangerously low after treatment. About 204 adults with solid tumors will be randomly assigned to one of the two groups for up to 14 days. The goal is to safely raise platelet counts and reduce bleeding risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER THERAPY-INDUCED THROMBOCYTOPENIA (CTIT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.